U.S. federal trademark · Serial No. 97830256
Scientific research in the nature of conducting clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
Medical treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
Organizing and recruiting patients for clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.